Abstract | BACKGROUND: OBJECTIVE: A method of reducing pain with BTX-B injection without reducing efficacy. This was evaluated in 2 BTX-A-resistant subjects and another BTX-B-naive subject. METHODS: Clinical evaluation and computer analysis of photographs were used to confirm efficacy to different dilutions of Type B toxin and confirm BTX-A resistance. A pilot study of 3 subjects involves BTX-B (usually pH 5.6) that was diluted with sodium bicarbonate to normalize the pH to 7.5 in the syringe immediately before injection. Pain assessment compared the different pH BTX-B solutions. RESULTS: Two patients with acquired resistance to 3 BTX-As in upper facial muscles responded to BTX-B. Injection pain of BTX-B changed to pH 7.5 was significantly reduced and retained efficacy over 10 weeks. CONCLUSION:
|
Authors | Philippa L Lowe, Nicholas J Lowe |
Journal | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
(Dermatol Surg)
Vol. 40
Issue 12
Pg. 1328-33
(Dec 2014)
ISSN: 1524-4725 [Electronic] United States |
PMID | 25350125
(Publication Type: Journal Article)
|
Chemical References |
- Neuromuscular Agents
- rimabotulinumtoxinB
- Botulinum Toxins, Type A
|
Topics |
- Adult
- Botulinum Toxins, Type A
(administration & dosage, chemistry)
- Drug Resistance
- Face
- Female
- Humans
- Hydrogen-Ion Concentration
- Injections
- Male
- Neuromuscular Agents
(administration & dosage, chemistry)
- Pain
(prevention & control)
- Pain Measurement
- Photography
- Treatment Outcome
|